Biogen Media |

All Press Releases

Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
4/14/08 6:30 pm EDT
Biogen Idec to Report First Quarter 2008 Financial Results on April 23, 2008
4/1/08 1:50 pm EDT
Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies
3/24/08 4:01 pm EDT
Biogen Idec to Present at the Cowen & Company 28th Annual Healthcare Conference
3/10/08 1:19 pm EDT
Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering
2/29/08 8:30 am EST
Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
2/14/08 8:30 am EST
Biogen Idec Reports Full Year and Fourth Quarter 2007 Results
2/6/08 7:15 am EST
Biogen Idec Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
1/31/08 4:01 pm EST
Biogen Idec Receives Director Nomination Proposal
1/28/08 7:00 am EST
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
1/25/08 1:30 am EST

Biogen Idec to Present at the Cowen & Company 28th Annual Healthcare Conference
3/10/08 1:19 pm EDT
Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering
2/29/08 8:30 am EST
Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
2/14/08 8:30 am EST
Biogen Idec Reports Full Year and Fourth Quarter 2007 Results
2/6/08 7:15 am EST
Biogen Idec Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
1/31/08 4:01 pm EST
Biogen Idec Receives Director Nomination Proposal
1/28/08 7:00 am EST
Biogen Idec to Present at the Wachovia 2008 Healthcare Conference
1/23/08 1:36 pm EST
Biogen Idec to Report Fourth Quarter and Full Year 2007 Financial Results on February 6, 2008
1/15/08 5:04 pm EST
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
1/14/08 3:38 pm EST
Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors
1/10/08 4:01 pm EST